HD Labs Tirzepatide 30mg Vial

Tirzepatide is a peptide studied extensively for its activity across key metabolic and incretin pathways. It functions as a dual receptor agonist, acting on:

• GLP-1 (glucagon-like peptide-1) receptors

• GIP (glucose-dependent insulinotropic polypeptide) receptors

Through this dual mechanism, tirzepatide has been investigated for its effects on insulin secretion, regulation of hepatic glucose production, delayed gastric emptying, and appetite-related signalling.

This product is supplied as a 30 mg lyophilised peptide vial, intended for purchasers who have independently researched the compound and are operating under appropriate professional guidance.

Clinical Trial Evidence (Phase 3)

Tirzepatide has undergone extensive Phase 3 clinical evaluation in large, controlled trials.

• In Phase 3 studies conducted under controlled conditions, tirzepatide demonstrated substantial and sustained reductions in body weight, with participants achieving average weight reductions of up to approximately 22–23% over 72 weeks, depending on dose and study protocol.

• Phase 3 programmes also evaluated long-term safety, tolerability, and metabolic outcomes, forming the basis for subsequent regulatory approvals in certain jurisdictions.

Outcomes observed in clinical trials are dependent on controlled protocols and do not guarantee similar results outside of clinical settings.

How Tirzepatide Compares

Tirzepatide is often discussed alongside other incretin-based peptides:

• Semaglutide functions as a GLP-1 receptor agonist only

• Tirzepatide is a dual agonist, targeting both GLP-1 and GIP receptors

• This dual activity differentiates tirzepatide from earlier single-pathway GLP-1 compounds

Important Information

• Supplied in lyophilised peptide format

• Requires reconstitution 
  

• Consultation with a licensed healthcare provider is essential prior to any consideration of use

• Clinical trial results may not reflect individual or real-world outcomes

This product is supplied strictly on an informed purchaser basis. By purchasing, you acknowledge that:

• You have independently researched tirzepatide and its regulatory status

• You have consulted, or will consult, a qualified healthcare professional prior to any use

• You understand that clinical trial outcomes do not constitute guarantees of effect

• The seller provides no medical advice, dosing guidance, or therapeutic claims

• The onus of lawful, safe, and appropriate use rests entirely with the purchaser